ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
View original at finance.yahoo.comImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities Preliminary Q1 2026 net product revenue of approximately $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 Consistent qua…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Following strong growth in 2025, ImmunityBio is focused on scaling in the U.S. and expanding across an increasing number of global markets
60% confidenceANKTIVA's continued momentum reflects growing physician adoption and disciplined commercial execution
60% confidenceFull enrollment of the pivotal BCG-naïve CIS trial with IDMC confirmation of adequate statistical power further strengthen the expanding body of clinical evidence supporting ANKTIVA in the NMIBC bladder cancer setting
60% confidenceSupplemental BLA submission for BCG-naïve indication is on track for 2026
60% confidenceThe sustained momentum of ANKTIVA reflects its growing commercial adoption in the BCG-unresponsive NMIBC CIS setting and feedback from treating urologists has been consistently positive
60% confidence